The Protective Role of Dexmedetomidine on Hepatic Injury of the Donor of Liver Transplant

The Protective Role of Dexmedetomidine on Hepatic Injury of the Donor of Liver Transplant: A Randomised Control Trial: A Randomised Control Trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR202404838380059

Enrollment

Registered

2024-04-25

Start date

2024-02-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaesthesia

Interventions

control group

dex group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Donors aged = 18 to = 45 years. - Both sexes. - Classified by American Society of Anesthesiologists (ASA) I and II who will be candidates to be donors of ALDLT.

Exclusion criteria

Exclusion criteria: - A patient refused to participate in the study. - Allergy to any of the study drugs by history. - A body-mass index higher than 35 kg/m². - Those on hypnotics or antidepressant drugs.

Design outcomes

Primary

Measure	Time frame
the level of human tumor necrosis factor-a (TNF-a) by enzyme-linked immunosorbent assay (ELISA) test.	—

Secondary

Measure	Time frame
• Liver profile: alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL) and international normalized ratio (INR). • Hemodynamic stability (heart rate, mean arterial blood pressure, and cardiac output by Electrical Cardiometry). • Opioid requirements.	—

Countries

Egypt

Contacts

Public Contacthanaa rashed

lecturer of anasthesia

hanaarashed2020@yahoo.com0248986754

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026